VRDN
Viridian Therapeutics, Inc.\DE
NASDAQ · Healthcare · Biotechnology · US
$24.67
−0.52%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 12.50x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 4.22x
- Price / sales
- 39.29x
- Price / cash flow
- -8.38x
Enterprise value
- Enterprise value
- $2.2B
- EV / sales
- 30.29x
- EV / EBITDA
- -5.86x
- EV / EBIT
- -5.32x
- Market cap
- $2.8B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026